View this email in your browser

MedNess: bite-size biopharma and medtech news

13th April, 2022
Subscribe here
MedNess This Week
HIGHLIGHTS
 
  Drug Approvals
European Commission approved CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma
“Advancing cell therapies is a significant part of our commitment to deliver innovative and potentially curative treatments in order to transform the lives of people living with cancer,” said Samit Hirawat, M.D., chief medical officer, Bristol Myers Squibb. “Breyanzi addresses an ongoing unmet need for patients in Europe battling relapsed or refractory large B-cell lymphoma who have few treatment options that provide long-term remission. The EC approval of Breyanzi is a significant step towards bringing the novel and personalized science of CAR T cell therapies to more patients around the world.”
  
  Regulatory News

Regulatory and Clinical Updates for Lifileucel in Melanoma announced
Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, “The favorable feedback received from the FDA on our potency assays and assay matrix brings Iovance a step closer to our submission of a BLA for lifileucel in metastatic melanoma. We look forward to bringing lifileucel to the market quickly to offer melanoma patients a new option following anti-PD-1 therapy.”
2022 AACR Annual Meeting Coverage
  1. Anaveon to present first clinical data from the Ph 1/2 study of ANV419
  2. Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod
  3. Coherus and Junshi Biosciences Present Results of Ph 3 Study of Toripalimab in 1L Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
  4. IO Biotech Announces Presentation of New Data from MM1636 Ph 1/2 Clinical Trial
Collated by: Richa Tewari, PhD 
Genes and Therapy
Lysogene enters collaboration with Yeda to develop gene therapy for GBA1 based neuronal diseases
Lysogene has entered into an exclusive worldwide license agreement with Yeda Research and Development Co Ltd, the commercial arm of the Weizmann Institute of Science, for the development and commercialization of a gene therapy candidate for the treatment of neuronopathic Gaucher disease and Parkinson disease (PD) with GBA1 mutations. Under the terms of the agreement, Lysogene will be responsible for the preclinical and clinical development, manufacturing, regulatory activities, and commercialization of the drug candidate, globally. Yeda Research and Development Co Ltd will be eligible for royalties and other payments.
MedNess Business
Onco News
Accord BioPharma and Foresee Pharmaceuticals Launch CAMCEVI™ (Leuprolide) Injection Emulsion in the US for the Treatment of Advanced Prostate Cancer in Adults
"The U.S. launch of CAMCEVI validates the importance of Foresee's pioneering Stabilized Injectable Formulation (SIF) technology and is a monumental step toward fulfilling our mission of improving on a standard of care," said Dr. Ben Chien, founder and Chairman of Foresee. "We know that Accord BioPharma shares in that important goal."
Twist Bioscience Signs Antibody Discovery Collaboration with MediSix Therapeutics to Develop T-cell Therapies
“We believe Twist’s exceptional antibody discovery and optimization platform and extensive libraries, coupled with the company’s ability to move quickly and efficiently, will support our efforts to develop effective immune cell therapies that specifically modulate relevant molecules and combat T-cell malignancies and autoimmune diseases,” said Andrew Bruce, CEO of MediSix Therapeutics. “We look forward to continued work with Twist as we build our pipeline.”
Collated by: Richa Tewari, PhD 
Editors' Desk
Richa Tewari, PhD
Oncology News
Debarati Banik
HealthIT
Sohini Dutta
BioPharma News
MedNess Plus
Shalini Roy Choudhury
Genes and Therapy
Managing Editor
Nisha Peter, PhD
Consulting Editor

 
Share Share
Tweet Tweet
Forward Forward
Subscribe
Disclaimer
The editors take care to share authentic information.  In case of any discrepancies please write to medness.newsletter@gmail.com
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Medness. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for Medness. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Copyright © 2019 MedNess , All rights reserved.
You are receiving this MedNess Newsletter as a subscriber on the list.

Cover Image : iStock
Images : Twitter , Unsplash.com
Content Editors: Richa Tewari , Esha Sehanobish , Rinki Saha ,  Shilpa Rawal, PhD ,  Debarati Banik  , Divyaanka Iyer , Arundithi Ananthanarayanan and Abhinav Dey 
Concept and Design: Ananda Ghosh and Nisha Peter
Our mailing address is:
MedNess
1150 First Ave. King of Prussia,, PA 19406

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.